NO20023175D0 - Camptothecin beta-alaninestere med topoisomerase I inhibering - Google Patents

Camptothecin beta-alaninestere med topoisomerase I inhibering

Info

Publication number
NO20023175D0
NO20023175D0 NO20023175A NO20023175A NO20023175D0 NO 20023175 D0 NO20023175 D0 NO 20023175D0 NO 20023175 A NO20023175 A NO 20023175A NO 20023175 A NO20023175 A NO 20023175A NO 20023175 D0 NO20023175 D0 NO 20023175D0
Authority
NO
Norway
Prior art keywords
topoisomerase
beta
camptothecin
inhibition
alanine esters
Prior art date
Application number
NO20023175A
Other languages
English (en)
Other versions
NO20023175L (no
Inventor
Monroe E Wall
Mansukh C Wani
Govindarajan Manikumar
Neelakantan Balasubramanian
Dolatrai Vyas
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20023175D0 publication Critical patent/NO20023175D0/no
Publication of NO20023175L publication Critical patent/NO20023175L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
NO20023175A 1999-12-29 2002-06-28 Kamptotecin beta-alaninestere med topoisomerase I inhibering NO20023175L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/474,099 US6288072B1 (en) 1999-12-29 1999-12-29 Camptothecin β-alanine esters with topoisomerase I inhibition
PCT/US2000/015033 WO2001049691A1 (en) 1999-12-29 2000-06-14 CAMPTOTHECIN β-ALANINE ESTERS WITH TOPOISOMERASE I INIBHITION

Publications (2)

Publication Number Publication Date
NO20023175D0 true NO20023175D0 (no) 2002-06-28
NO20023175L NO20023175L (no) 2002-08-29

Family

ID=23882177

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023175A NO20023175L (no) 1999-12-29 2002-06-28 Kamptotecin beta-alaninestere med topoisomerase I inhibering

Country Status (11)

Country Link
US (1) US6288072B1 (no)
EP (1) EP1254141B1 (no)
JP (1) JP4704648B2 (no)
KR (1) KR100762556B1 (no)
AT (1) ATE302204T1 (no)
AU (1) AU784602B2 (no)
CA (1) CA2396030C (no)
DE (1) DE60022095T2 (no)
ES (1) ES2246864T3 (no)
NO (1) NO20023175L (no)
WO (1) WO2001049691A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403604B1 (en) * 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003043584A2 (en) * 2001-11-20 2003-05-30 University Of Kentucky Research Foundation Engineered liposomal particles containing core-loaded pro-drugs for the controlled release of camptothecins
US7071202B2 (en) * 2002-02-21 2006-07-04 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
ITRM20020306A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
US7071204B2 (en) 2003-06-30 2006-07-04 Research Triangle Institute Camptothecin analogs having an E-ring ketone
US9556192B2 (en) 2012-10-30 2017-01-31 Nerviano Medical Sciences S.R.L. Functionalized 9-bromo-camptothecin derivatives
WO2018209293A2 (en) 2017-05-11 2018-11-15 The Regents Of The University Of California Nanoscale multiple emulsions and nanoparticles
CN111171041B (zh) * 2018-11-12 2021-07-27 中国海洋大学 20位取代的喜树碱衍生物及其制备方法和应用
CN111484501A (zh) * 2020-04-22 2020-08-04 沈阳药科大学 羟基喜树碱亚油酸酯小分子前药及其自组装纳米粒的构建

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US564619A (en) * 1896-07-28 Apparatus for dyeing
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5106742A (en) 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US4894456A (en) 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5364858A (en) 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5122526A (en) 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5053512A (en) 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5227380A (en) 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5049668A (en) 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5180722A (en) 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5340817A (en) 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US5122606A (en) 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
DE4119981C1 (no) 1991-06-18 1993-01-21 Fa. Carl Freudenberg, 6940 Weinheim, De
DE69209969T2 (de) * 1991-10-29 1996-09-12 Glaxo Wellcome Inc Wasserlösliche Camptothecinderivate
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5496830A (en) 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
US5614529A (en) 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
GB9504065D0 (en) * 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
JPH08333370A (ja) 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
ES2247606T3 (es) * 1995-11-02 2006-03-01 Osi Pharmaceuticals, Inc. Metodo para preparar derivados de camptotecina.
WO1997019085A1 (en) 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties

Also Published As

Publication number Publication date
JP2003519234A (ja) 2003-06-17
US6288072B1 (en) 2001-09-11
WO2001049691A1 (en) 2001-07-12
DE60022095T2 (de) 2006-06-08
EP1254141A1 (en) 2002-11-06
KR100762556B1 (ko) 2007-10-04
AU784602B2 (en) 2006-05-11
DE60022095D1 (en) 2005-09-22
CA2396030C (en) 2011-03-15
EP1254141A4 (en) 2003-05-02
ATE302204T1 (de) 2005-09-15
ES2246864T3 (es) 2006-03-01
EP1254141B1 (en) 2005-08-17
NO20023175L (no) 2002-08-29
KR20020081682A (ko) 2002-10-30
AU5453800A (en) 2001-07-16
JP4704648B2 (ja) 2011-06-15
CA2396030A1 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
HK1049664A1 (en) Quinazoline derivatives as vegf inhibitors
PL350911A1 (en) Inhibitors of impdh enzyme
AU2001228309A1 (en) N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
HUP0101793A3 (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
NO20054715L (no) Fremgangsmater og mellomprodukter for fremstilling av anti-cancer forbindelser
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
ID20637A (id) Metode untuk menghambat pembentukan sulfida biogenik
IL145764A0 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
NO20023175D0 (no) Camptothecin beta-alaninestere med topoisomerase I inhibering
PT1144425E (pt) Derivados de monossacaridos como inibidores de adesao celular
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
DE60038350D1 (de) Angiotensin-Converting-Enzyme-Hemmer
AU7125700A (en) Enzyme inhibitors
GB9924522D0 (en) Enzyme inhibitors
NO20031745L (no) Inhibisjon av vekstfaktoravhengigheten til tumorceller
WO2005009347A3 (en) 7-substituted camptothecin and camptothecin analogs and methods for preparing same
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
AU7127000A (en) Enzyme inhibitors
AU1070901A (en) Method of treating cells of the prostate prophylactically or therapeutically
AU2003300551A8 (en) Compounds for the inhibition of non-proteolytic enzymes
ATE279113T1 (de) Hypoxanthin- und thiohypxanthin-verbindungen
WO2005005600A3 (en) Camptothecin analogs having an e-ring ketone
AU7951600A (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
AU2337701A (en) Beta-tubulin inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application